Detalhe da pesquisa
1.
A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo.
Curr Issues Mol Biol;
45(9): 7087-7096, 2023 Aug 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37754232
2.
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
Cancer Immunol Immunother;
72(9): 2939-2948, 2023 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37247022
3.
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
Br J Clin Pharmacol;
85(11): 2499-2511, 2019 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31271459
4.
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Am J Hematol;
92(10): E575-E583, 2017 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28699256
5.
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.
Mol Med;
22: 632-642, 2016 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27455414
6.
The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
Cancer Immunol Immunother;
65(10): 1169-75, 2016 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27506529
7.
Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia.
Am J Hematol;
96(4): E114-E117, 2021 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33476436
8.
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Mol Med;
21(1): 824-832, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26322845
9.
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
Br J Haematol;
171(4): 530-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26343802
10.
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Br J Haematol;
165(3): 375-81, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24606326
11.
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Br J Haematol;
165(4): 510-8, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24579926
12.
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.
Am J Hematol;
94(11): E291-E294, 2019 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31379016
13.
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Br J Haematol;
162(5): 639-47, 2013 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23834234
14.
Checkpoint inhibition in hematologic malignancies.
Front Oncol;
13: 1288172, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37920162
15.
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Clin Cancer Res;
29(10): 1869-1878, 2023 05 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36826995
16.
Adverse health effects of marijuana use.
N Engl J Med;
371(9): 878-9, 2014 08 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25162901
17.
Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.
Mol Pharm;
9(6): 1727-35, 2012 Jun 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22530955
18.
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Leuk Res;
119: 106885, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35738024
19.
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.
Cancer Immunol Immunother;
60(6): 771-80, 2011 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21347809
20.
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.
Clin Cancer Res;
27(17): 4726-4736, 2021 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34088724